{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T16:33:54Z","timestamp":1789403634530,"version":"build-2803163510"},"reference-count":46,"publisher":"Informa UK Limited","issue":"8","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Immunotherapy"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.2217\/imt-2022-0298","type":"journal-article","created":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T09:08:37Z","timestamp":1680599317000},"page":"553-563","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":21,"title":["Clinical Efficacy and Safety of Efgartigimod for Treatment of Myasthenia Gravis"],"prefix":"10.1080","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9949-7878","authenticated-orcid":false,"given":"Ajith","family":"Sivadasan","sequence":"first","affiliation":[{"name":"Ellen & Martin Prosserman Centre for Neuromuscular Diseases, Toronto General Hospital, University Health Networkand University of Toronto, 5EC-309, TGH, 200 Elizabeth Street, Toronto, ON M5G 2C4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5805-4883","authenticated-orcid":false,"given":"Vera","family":"Bril","sequence":"additional","affiliation":[{"name":"Ellen & Martin Prosserman Centre for Neuromuscular Diseases, Toronto General Hospital, University Health Networkand University of Toronto, 5EC-309, TGH, 200 Elizabeth Street, Toronto, ON M5G 2C4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,4,4]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1602678"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00145-3"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00538"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2016.2277"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2016.2032"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27521"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2012.437"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002790"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011124"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756285617749134"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31821e5505"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1009433"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-9987.2009.00751.x"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI97911"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2006.02408.x"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.07.015"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri2155"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0402970101"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.24815"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756286421997381"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2019.03.001"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27341"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007600"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00159-9"},{"issue":"2","key":"e_1_3_3_27_1","first-page":"S37","article-title":"Long-term safety, tolerability, and efficacy of efgartigimod in patients with generalized myasthenia gravis: interim results of the ADAPT+ study","volume":"99","author":"Howard JF","year":"2022","unstructured":"Howard JF Jr , BrilV , VuTet al. Long-term safety, tolerability, and efficacy of efgartigimod in patients with generalized myasthenia gravis: interim results of the ADAPT+ study. Neurology99(2 Suppl. 23), S37\u2013S38 (2022).","journal-title":"Neurology"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/jca.22002"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/08916934.2016.1214823"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/08916934.2022.2104261"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01678-3"},{"key":"e_1_3_3_32_1","unstructured":"Vyvgart\u2122 (efgartigimod alfa-fcab) injection for intravenous use: US highlights of prescribing information. Argenx Gent Belgium (2021). https:\/\/argenx.com\/product\/vyvgart-prescribing-information.pdf"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20782"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004676"},{"key":"e_1_3_3_35_1","unstructured":"Argenx announces positive topline phase 3 data from ADAPTSC study evaluating subcutaneous efgartigimod for generalized myasthenia gravis. (2022). www.businesswire.com\/news\/home\/20220321005941\/en\/argenx-Announces-Positive-Topline-Phase-3-Data-FromADAPT-SC-Study-Evaluating-Subcutaneous-Efgartigimod-forGeneralized-Myasthenia-Gravis (Accessed 1December2022)."},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-021-01175-7"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011108"},{"key":"e_1_3_3_38_1","unstructured":"UCB. UCB announces positive phase 3 results for rozanolixizumab in generalized myasthenia gravis. www.ucb.com\/stories-media\/Press-Releases\/article\/UCB-announces-positive-Phase-3-results-for-rozanolixizumabin-generalized-myasthenia-gravis (Accessed 1December2022)."},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2019.02.058"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.11.017"},{"key":"e_1_3_3_41_1","unstructured":"Evaluating the pharmacokinetics pharmacodynamics and safety of efgartigimod administered intravenously in children with generalized myasthenia gravis. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04833894 (Accessed 6February2022)."},{"key":"e_1_3_3_42_1","unstructured":"Evaluating long-term safety of efgartigimod administered intravenously in children with generalized MG. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05374590 (Accessed 6February2022)."},{"key":"e_1_3_3_43_1","unstructured":"Evaluating the long-term safety and tolerability of efgartigimod PH20 SC administered subcutaneously in patients with generalized MG (ADAPTsc+). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04818671 (Accessed 6February2022)."},{"key":"e_1_3_3_44_1","unstructured":"A phase 3b randomized open-label parallel-group study to evaluate different dosing regimens of intravenous efgartigimod to maximize and maintain clinical benefit in patients with generalized MG (ADAPT NXT). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04980495 (Accessed 6February2022)."},{"key":"e_1_3_3_45_1","unstructured":"A phase 2 trial to investigate the efficacy safety and tolerability of efgartigimod PH20 SC in adult patients with CIDP. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04281472 (Accessed 6February2022)."},{"key":"e_1_3_3_46_1","unstructured":"Open-label extension of the ARGX-113-1802 trial to investigate the long-term safety tolerability and efficacy of efgartigimod PH20 SC in patients with CIDP. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04280718 (Accessed 6February2022)."},{"key":"e_1_3_3_47_1","unstructured":"A study to investigate the efficacy and safety of efgartigimod PH20 SC in adult participants with active idiopathic inflammatory myopathy. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05523167 (Accessed 6February2022)."},{"key":"e_1_3_3_48_1","unstructured":"A study of nipocalimab administered to adults with generalized myasthenia gravis. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04951622 (Accessed 6February2022)."}],"container-title":["Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/imt-2022-0298","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T11:48:52Z","timestamp":1715946532000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/imt-2022-0298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,4]]},"references-count":46,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.2217\/imt-2022-0298"],"URL":"https:\/\/doi.org\/10.2217\/imt-2022-0298","relation":{},"ISSN":["1750-743X","1750-7448"],"issn-type":[{"value":"1750-743X","type":"print"},{"value":"1750-7448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-12-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}